Seasonal influenza vaccinations: Specialized products for different target groups

Vaccine

Volumn 28, Issue SUPPL. 4, 2010, Pages

  Monto, Arnold S ^a  

^a UNIVERSITY OF MICHIGAN SCHOOL OF PUBLIC HEALTH   (United States)

Author keywords

Seasonal influenza vaccination; Specialized vaccines; Target group; Vaccination strategy; Vaccine development

Indexed keywords

INACTIVATED VACCINE; INFLUENZA VACCINE; LIVE VACCINE; IMMUNOLOGICAL ADJUVANT;

ANTIBODY TITER; ARTICLE; DISEASE SURVEILLANCE; DRUG FORMULATION; HEALTH SURVEY; HOSPITALIZATION; HUMAN; INFLUENZA VACCINATION; INFLUENZA VIRUS A H3N2; MEDICAID; NONHUMAN; PNEUMONIA; PRIORITY JOURNAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SEASONAL INFLUENZA; WORLD HEALTH ORGANIZATION; ADOLESCENT; ADULT; AGED; CHILD; INFANT; INFLUENZA, HUMAN; MIDDLE AGED; PRESCHOOL CHILD; VERY ELDERLY; YOUNG ADULT;

ADJUVANTS, IMMUNOLOGIC; ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; CHILD; CHILD, PRESCHOOL; HUMANS; INFANT; INFLUENZA VACCINES; INFLUENZA, HUMAN; MIDDLE AGED; VACCINES, INACTIVATED; YOUNG ADULT;

EID: 77955627664     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vaccine.2010.08.025     Document Type: Article

References (46)

1. Davenport F.M. Control of influenza. Med J Aust 1973, (Suppl):33-38.
2. Francis T.J. The development of the 1943 vaccination study of the Commission on influenza. Am J Hyg 1945, 42:1-11.
3. Hirst G.K., Rickard E.R., Whitman L., Horsfall F.L. Antibody response of human beings following vaccination with influenza viruses. J Exp Med 1942, 75:495-511.
4. Kilbourne E.D., Smith C., Brett I., Pokorny B.A., Johansson B., Cox N. The total influenza vaccine failure of 1947 revisited: major intrasubtypic antigenic change can explain failure of vaccine in a post-World War II epidemic. Proc Natl Acad Sci U S A 2002, 99:10748-10752.
5. de Jong J.C., Beyer W.E., Palache A.M., Rimmelzwaan G.F., Osterhaus A.D. Mismatch between the 1997/1998 influenza vaccine and the major epidemic A(H3N2) virus strain as the cause of an inadequate vaccine-induced antibody response to this strain in the elderly. J Med Virol 2000, 61:94-99.
6. Treanor J. Influenza vaccine-outmaneuvering antigenic shift and drift. N Engl J Med 2004, 350:218-220.
7. Smith D.J., Lapedes A.S., de Jong J.C., Bestebroer T.M., Rimmelzwaan G.F., Osterhaus A.D., et al. Mapping the antigenic and genetic evolution of influenza virus. Science 2004, 305:371-376.
8. Ohmit S.E., Victor J.C., Rotthoff J.R., Teich E.R., Truscon R.K., Baum L.L., et al. Prevention of antigenically drifted influenza by inactivated and live attenuated vaccines. N Engl J Med 2006, 355:2513-2522.
9. Monto A.S., Ohmit S.E., Petrie J.G., Johnson E., Truscon R., Teich E., et al. Comparative efficacy of inactivated and live attenuated influenza vaccines. N Engl J Med 2009, 361:1260-1267.
10. Thompson W.W., Shay D.K., Weintraub E., Brammer L., Cox N., Anderson L.J., et al. Mortality associated with influenza and respiratory syncytial virus in the United States. JAMA 2003, 289:179-186.
11. Thompson W.W., Shay D.K., Weintraub E., Brammer L., Bridges C.B., Cox N.J., et al. Influenza-associated hospitalizations in the United States. JAMA 2004, 292:1333-1340.
12. Govaert T.M., Thijs C.T., Masurel N., Sprenger M.J., Dinant G.J., Knottnerus J.A. The efficacy of influenza vaccination in elderly individuals. A randomized double-blind placebo-controlled trial. JAMA 1994, 272:1661-1665.
13. Foster D.A., Talsma A., Furumoto-Dawson A., Ohmit S.E., Margulies J.R., Arden N.H., et al. Influenza vaccine effectiveness in preventing hospitalization for pneumonia in the elderly. Am J Epidemiol 1992, 136:296-307.
14. Ohmit S.E., Monto A.S. Influenza vaccine effectiveness in preventing hospitalization among the elderly during influenza type A and type B seasons. Int J Epidemiol 1995, 24:1240-1248.
15. Fedson D.S., Wajda A., Nicol J.P., Hammond G.W., Kaiser D.L., Roos L.L. Clinical effectiveness of influenza vaccination in Manitoba. JAMA 1993, 270:1956-1961.
16. Nichol K.L., Margolis K.L., Wuorenma J. Von Sternberg T. The efficacy and cost effectiveness of vaccination against influenza among elderly persons living in the community. N Engl J Med 1994, 331:778-784.
17. Nichol K.L. Wuorenma J, von Sternberg T. Benefits of influenza vaccination for low-, intermediate-, and high-risk senior citizens. Arch Intern Med 1998, 158:1769-1776.
18. Nichol K.L., Nordin J.D., Nelson D.B., Mullooly J.P., Hak E. Effectiveness of influenza vaccine in the community-dwelling elderly. N Engl J Med 2007, 357:1373-1381.
19. Jackson L.A., Jackson M.L., Nelson J.C., Neuzil K.M., Weiss N.S. Evidence of bias in estimates of influenza vaccine effectiveness in seniors. Int J Epidemiol 2006, 35:337-344.
20. Jackson L.A., Nelson J.C., Benson P., Neuzil K.M., Reid R.J., Psaty B.M., et al. Functional status is a confounder of the association of influenza vaccine and risk of all cause mortality in seniors. Int J Epidemiol 2006, 35:345-352.
21. Jackson M.L., Nelson J.C., Weiss N.S., Neuzil K.M., Barlow W., Jackson L.A. Influenza vaccination and risk of community-acquired pneumonia in immunocompetent elderly people: a population-based, nested case-control study. Lancet 2008, 372:398-405.
22. Simonsen L., Taylor R.J., Viboud C., Miller M.A., Jackson L.A. Mortality benefits of influenza vaccination in elderly people: an ongoing controversy. Lancet Infect Dis 2007, 7:658-666.
23. Monto A.S., Rotthoff J., Teich E., Herlocher M.L., Truscon R., Yen H.L., et al. Detection and control of influenza outbreaks in well-vaccinated nursing home populations. Clin Infect Dis 2004, 39:459-464.
24. McElhaney J.E. The unmet need in the elderly: designing new influenza vaccines for older adults. Vaccine 2005, 23(Suppl 1):S10-25.
25. Neuzil K.M., Mellen B.G., Wright P.F. Mitchel EF Jr. Griffin MR. The effect of influenza on hospitalizations, outpatient visits, and courses of antibiotics in children. N Engl J Med 2000, 342:225-231.
26. Walter E.B., Neuzil K.M., Zhu Y., Fairchok M.P., Gagliano M.E., Monto A.S., et al. Influenza vaccine immunogenicity in 6- to 23-month-old children: are identical antigens necessary for priming? Pediatrics 2006, 118:e570-e578.
27. Englund J.A., Walter E.B., Fairchok M.P., Monto A.S., Neuzil K.M. A comparison of 2 influenza vaccine schedules in 6- to 23-month-old children. Pediatrics 2005, 115:1039-1047.
28. Ujhazy V. Clinical trials of oil-adjuvant influenza vaccines, 1960-3. report to the medical research council by its committee on influenza and other respiratory virus vaccines. Br Med J 1964, 2:267-271.
29. Treanor J.J., Campbell J.D., Zangwill K.M., Rowe T., Wolff M. Safety and immunogenicity of an inactivated subvirion influenza A (H5N1) vaccine. N Engl J Med 2006, 354:1343-1351.
30. Stephenson I., Bugarini R., Nicholson K.G., Podda A., Wood J.M., Zambon M.C., et al. Cross-reactivity to highly pathogenic avian influenza H5N1 viruses after vaccination with nonadjuvanted and MF59-adjuvanted influenza A/Duck/Singapore/97 (H5N3) vaccine: a potential priming strategy. J Infect Dis 2005, 191:1210-1215.
31. Leroux-Roels I., Borkowski A., Vanwolleghem T., Dramé M., Clement F., Hons E., et al. Antigen sparing and cross-reactive immunity with an adjuvanted rH5N1 prototype pandemic influenza vaccine: a randomised controlled trial. Lancet 2007, 370:580-589.
32. Leroux-Roels I., Roman F., Forgus S., Maes C., De Boever F., Dramé M., et al. Priming with AS03 A-adjuvanted H5N1 influenza vaccine improves the kinetics, magnitude and durability of the immune response after a heterologous booster vaccination: an open non-randomised extension of a double-blind randomised primary study. Vaccine 2010, 28:849-857.
33. O'Hagan D.T., Wack A., Podda A. MF59 is a safe and potent vaccine adjuvant for flu vaccines in humans: what did we learn during its development?. Clin Pharmacol Ther 2007, 82:740-744.
34. Keitel W.A., Atmar R.L., Cate T.R., Petersen N.J., Greenberg S.B., Ruben F., et al. Safety of high doses of influenza vaccine and effect on antibody responses in elderly persons. Arch Intern Med 2006, 166:1121-1127.
35. Falsey A.R., Treanor J.J., Tornieporth N., Capellan J., Gorse G.J. Randomized, double-blind controlled phase 3 trial comparing the immunogenicity of high-dose and standard-dose influenza vaccine in adults 65 years of age and older. J Infect Dis 2009, 200:172-180.
36. Katz J.M., Webster R.G. Efficacy of inactivated influenza A virus (H3N2) vaccines grown in mammalian cells or embryonated eggs. J Infect Dis 1989, 160:191-198.
37. Frace A.M., Klimov A.I., Rowe T., Black R.A., Katz J.M. Modified M2 proteins produce heterotypic immunity against influenza A virus. Vaccine 1999, 17:2237-2244.
38. Neirynck S., Deroo T., Saelens X., Vanlandschoot P., Jou W.M., Fiers W. A universal influenza A vaccine based on the extracellular domain of the M2 protein. Nat Med 1999, 5:1157-1163.
39. Monto A.S., Kioumehr F. The Tecumseh Study of Respiratory Illness. IX. Occurrence of influenza in the community, 1966-1971. Am J Epidemiol 1975, 102:553-563.
40. Elveback L.R., Fox J.P., Ackerman E., Langworthy A., Boyd M., Gatewood L. An influenza simulation model for immunization studies. Am J Epidemiol 1976, 103:152-165.
41. Monto A.S., Davenport F.M., Napier J.A., Francis T. Modification of an outbreak of influenza in Tecumseh, Michigan by vaccination of schoolchildren. J Infect Dis. 1970, 122:16-25.
42. Reichert T.A., Sugaya N., Fedson D.S., Glezen W.P., Simonsen L., Tashiro M. The Japanese experience with vaccinating schoolchildren against influenza. N Engl J Med 2001, 344:889-896.
43. Loeb M., Russell M.L., Moss L., Fonseca K., Fox J., Earn D.J., et al. Effect of influenza vaccination of children on infection rates in Hutterite communities: a randomized trial. JAMA 2010, 303:943-950.
44. Belshe R.B., Mendelman P.M., Treanor J., King J., Gruber W.C., Piedra P., et al. The efficacy of live attenuated, cold-adapted, trivalent, intranasal influenzavirus vaccine in children. N Engl J Med 1998, 338:1405-1412.
45. Belshe R.B., Gruber W.C., Mendelman P.M., Cho I., Reisinger K., Block S.L., et al. Efficacy of vaccination with live attenuated, cold-adapted, trivalent, intranasal influenza virus vaccine against a variant (A/Sydney) not contained in the vaccine. J Pediatr 2000, 136:168-175.
46. Belshe R.B., Edwards K.M., Vesikari T., Black S.V., Walker R.E., Hultquist M., et al. Live attenuated versus inactivated influenza vaccine in infants and young children. N Engl J Med 2007, 356:685-696.